Carrion A, Piñero A, Raventós C, Lozano F, Díaz F, Morote J
Departamento de Urología, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España.
Departamento de Urología, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España.
Actas Urol Esp (Engl Ed). 2019 Jul-Aug;43(6):277-283. doi: 10.1016/j.acuro.2019.01.006. Epub 2019 Apr 26.
To compare perioperative outcomes and complications of robot assisted radical cystectomy (RARC) with extracorporeal (ECUD) vs. intracorporeal urinary diversion (ICUD) for bladder cancer.
Retrospective revision of 43 patients who underwent RARC for bladder cancer between 2015-2018 with at least 3 months of follow-up. The analysis included the initial series of RARC performed by one surgeon with extensive experience in open radical cystectomy.
Forty-three patients, 40 men (93%) and 3 women (7%), with a median age of 65 years (44-83) and mean follow-up of 27.7 months (±20.1) underwent RARC. A ECUD was performed in 22 cases (51%), of whom 10 were ileal conduits (45.5%) and 12 neobladders (54.5), and ICUD in 21 cases (49%), of whom 14 were ileal conduits (66.7%) and 7 neobladders (33.3%). Clinical and preoperative characteristics were similar in both groups. The median operative time was 360 minutes (240-540) and length of hospital stay was 12 days (7-73). Thirty-five patients (81%) had postoperative complications, of whom 10 (23%) were major. Operative time, peroperative complications, pathological stage, positive margins, and number of lymph nodes removed did not significantly differ among groups. Patients who underwent ECUD had a higher rate of uretero-ileal strictures than those with ICUD (45.5% vs. 14.3%, P=.026). Among the neobladders, the ECUD developed a higher rate of urethro-neobladder stricture than the ICUD (33% vs. 0%, P=.044).
RARC with ICUD achieved peroperative outcomes and complication rates comparable than those with ECUD. The ICUD could reduce the risk of developing uretero-ileal and urethro-neobladder strictures.
比较机器人辅助根治性膀胱切除术(RARC)中采用体外尿流改道(ECUD)与体内尿流改道(ICUD)治疗膀胱癌的围手术期结局和并发症。
回顾性分析2015年至2018年间43例行RARC治疗膀胱癌且至少随访3个月的患者。分析内容包括由一位在开放性根治性膀胱切除术方面经验丰富的外科医生开展的首批RARC手术。
43例患者,40例男性(93%),3例女性(7%),中位年龄65岁(44 - 83岁),平均随访27.7个月(±20.1),接受了RARC手术。22例(51%)患者采用ECUD,其中10例为回肠膀胱术(45.5%),12例为新膀胱术(54.5%);21例(49%)患者采用ICUD,其中14例为回肠膀胱术(66.7%),7例为新膀胱术(33.3%)。两组的临床和术前特征相似。中位手术时间为360分钟(240 - 540分钟),住院时间为12天(7 - 73天)。35例患者(81%)出现术后并发症,其中10例(23%)为严重并发症。手术时间、术中并发症、病理分期、切缘阳性情况及切除淋巴结数量在两组间无显著差异。采用ECUD的患者输尿管 - 回肠狭窄发生率高于采用ICUD的患者(45.5%对14.3%,P = 0.026)。在新膀胱术中,采用ECUD的患者尿道 - 新膀胱狭窄发生率高于采用ICUD的患者(33%对0%,P = 0.044)。
RARC联合ICUD的围手术期结局和并发症发生率与联合ECUD相当。ICUD可降低输尿管 - 回肠和尿道 - 新膀胱狭窄的发生风险。